instruction
stringclasses 1
value | input
stringlengths 104
436
| output
stringlengths 45
55
| text
stringlengths 247
577
|
|---|---|---|---|
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3, Anti-CD38 MAb
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |
Identify the study with the following condition. | Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3 | Popular Name is ALCYONE, Study ID is NCT02195479 | ### Instruction:
Identify the study with the following condition.
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb, Phase 3
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479 |